[go: up one dir, main page]

HK40060391A - Combination of gaboxadol and lithium for the treatment of psychiatric disorders - Google Patents

Combination of gaboxadol and lithium for the treatment of psychiatric disorders Download PDF

Info

Publication number
HK40060391A
HK40060391A HK62022050679.9A HK62022050679A HK40060391A HK 40060391 A HK40060391 A HK 40060391A HK 62022050679 A HK62022050679 A HK 62022050679A HK 40060391 A HK40060391 A HK 40060391A
Authority
HK
Hong Kong
Prior art keywords
gaboxadol
lithium
treatment
combination
psychiatric disorders
Prior art date
Application number
HK62022050679.9A
Other languages
Chinese (zh)
Inventor
帕维尔·奥斯滕
克莉丝汀·鲍德温
罗伯特·德维塔
Original Assignee
Certego治疗公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Certego治疗公司 filed Critical Certego治疗公司
Publication of HK40060391A publication Critical patent/HK40060391A/en

Links

HK62022050679.9A 2018-11-21 2019-11-21 Combination of gaboxadol and lithium for the treatment of psychiatric disorders HK40060391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62/770,287 2018-11-21
US62/879,921 2019-07-29

Publications (1)

Publication Number Publication Date
HK40060391A true HK40060391A (en) 2022-05-13

Family

ID=

Similar Documents

Publication Publication Date Title
EP3746135A4 (en) Methods and compounds for treating disorders
EP3863630A4 (en) Compositions and methods for the treatment of presbyopia
IL287280A (en) Compounds and methods for the treatment of ocular disorders
EP3634282A4 (en) Methods and apparatuses for the thermal treatment of neurologic and psychiatric disorders
EP3775263A4 (en) Compositions and methods for the treatment of acne
EP3651747A4 (en) Compositions and methods for the treatment of eye disorders
IL283948A (en) Methods for the treatment of depression
IL287264A (en) Compounds and methods for the treatment of ocular disorders
EP3856169A4 (en) Methods of treating myeloproliferative disorders
AU2019206314B2 (en) Compositions and methods for treating retinal disorders
IL277805A (en) Use of gaboxadol in the treatment of substance use disorders
EP3866861A4 (en) Methods for treating and monitoring progranulin-associated disorders
IL283312A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
EP3856189A4 (en) Methods of treating myeloproliferative disorders
HK40060391A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
EP3585420A4 (en) Peptides and methods of treating dystrophy-related disorders using the same
HK40119093A (en) Methods for the treatment of cysteamine sensitive disorders
HK40062407A (en) Methods for the treatment of depression
HK40045533A (en) Treatment of disorders with tasimelteon
HK40058230A (en) Material and methods for the treatment of gastro-intestinal disorders
HK40053233A (en) Antibodies for the treatment of synucleinopathies and neuroinflammation
HK40060173A (en) Compositions and methods for the treatment of estrogen-dependent disorders
HK40059029A (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
EP3880201A4 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
HK40055553A (en) Methods of treating myeloproliferative disorders